Back to Browse Journals » Vascular Health and Risk Management » Volume 6

Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia

Authors Ian Hamilton-Craig, Karam Kostner, David Colquhoun, et al

Published 10 November 2010 Volume 2010:6 Pages 1023—1037

DOI http://dx.doi.org/10.2147/VHRM.S13496

Review by Single-blind

Peer reviewer comments 2

Ian Hamilton-Craig1, Karam Kostner2, David Colquhoun2, Stan Woodhouse2
1Griffith University School of Medicine, Southport, Queensland, Australia; 2University of Queensland, Brisbane, Queensland, Australia

Abstract: High-dose potent statin therapy in combination with ezetimibe is now standard practice for the treatment of adult patients with heterozygous familial hypercholesterolemia (heFH), as the result of numerous studies in patients with primary hypercholesterolemia or heFH. These studies have shown the combination to be both effective and safe in the short to medium term. Recently, short-term ezetimibe therapy has also been shown to be effective and safe in combination with statin therapy for children and adolescents with heFH. Effective statin–ezetimibe combination therapy is capable of achieving near-normal lipid profiles in heFH patients, with expected improvement in risk for cardiovascular disease (CVD) and improved life expectancy resulting predominantly from reduction in levels of low-density lipoprotein cholesterol. There are few data to support a pleiotropic action of ezetimibe with regard to CVD benefit, unlike therapy with statins. No serious and unexpected clinical adverse effects of combination statin–ezetimibe therapy have emerged till date, although data are limited in children and adolescents, for whom longer-term studies are required. Recent data suggesting possible proatherogenic effects of ezetimibe require confirmation. One large long-term randomized controlled clinical outcomes trial is in progress in non-FH patients to determine the efficacy and safety of ezetimibe therapy; it is unlikely that such a trial will ever be performed in patients with FH.

Keywords: familial hypercholesterolemia, ezetimibe, statin, combination therapy, low-density lipoprotein cholesterol

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] View Full Text [HTML] 

 

Other article by this author:

Lipid-modifying therapy in the elderly

Hamilton-Craig I, Colquhoun D, Kostner K, Woodhouse S, d'Emden M

Vascular Health and Risk Management 2015, 11:251-263

Published Date: 14 May 2015

Readers of this article also read:

Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy

William Insull Jr, Peter P Toth, H Robert Superko, et al

Vascular Health and Risk Management 2010, 6:1065-1075

Published Date: 24 November 2010

Computerized history-taking as a tool to manage dyslipidemia

David Zakim, Christine Fritz, Niko Braun, et al

Vascular Health and Risk Management 2010, 6:1039-1046

Published Date: 12 November 2010

Impact of a diabetic foot care education program on lower limb amputation rate

Abdullah M Al-Wahbi

Vascular Health and Risk Management 2010, 6:923-934

Published Date: 11 October 2010

Costs and outcomes of noncardioembolic ischemic stroke in a managed care population

Nicole M Engel-Nitz, Stephen D Sander, Carolyn Harley, et al

Vascular Health and Risk Management 2010, 6:905-913

Published Date: 5 October 2010

Benefits of statin therapy and compliance in high risk cardiovascular patients

Joel A Lardizabal, Prakash C Deedwania

Vascular Health and Risk Management 2010, 6:843-853

Published Date: 23 September 2010

Lifestyle diseases and cardiovascular risk factors are interrelated to deficiencies of major substrates in ATP synthesis

Jørn Ditzel, Hans-Henrik Lervang

Vascular Health and Risk Management 2010, 6:829-836

Published Date: 17 September 2010

Current and emerging therapeutic options for the treatment of chronic chagasic cardiomyopathy

Claudio A Muratore, Adrian Baranchuk

Vascular Health and Risk Management 2010, 6:593-601

Published Date: 14 July 2010

Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure

Inder S Anand, Anita Deswal, Dean J Kereiakes, et al

Vascular Health and Risk Management 2010, 6:449-455

Published Date: 1 June 2010

Atorvastatin in stroke: a review of SPARCL and subgroup analysis

Branko N Huisa, Andrew B Stemer, Justin A Zivin

Vascular Health and Risk Management 2010, 6:229-236

Published Date: 30 March 2010

Aspirin and clopidogrel resistance: methodological challenges and opportunities

Armen Yuri Gasparyan

Vascular Health and Risk Management 2010, 6:109-112

Published Date: 2 March 2010